在小鼠和小猪中产生长效葡萄糖反应性胰岛素复合物
Haodong Zhang1, Qian Liang2, Weinan Jiang3
1State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
Journal of the American Chemical Society
|October 23, 2025
概括
这项研究使用功能化聚合物提出了一种新型的葡萄糖反应性胰岛素配方. 在患有糖尿病的小猪中,新配方成功地维持了正常的血糖水平192小时.
科学领域:
- 生物材料科学
- 内分泌学
- 药物输送系统
背景情况:
- 通过模仿天然胰岛素分泌,旨在改善糖尿病的治疗.
- 目前配方面临的挑战是失控的胰岛素释放和潜在的低血糖事件.
- 聚合物和胰岛素之间的静电相互作用是控制释放的关键.
研究的目的:
- 开发一种安全有效的葡萄糖反应性胰岛素配方,用于皮下注射.
- 为了解决现有配方中失控胰岛素释放和低血糖的局限性.
- 为了提高胰岛素的治疗指数.
主要方法:
- 开发了一种配方,其中复合人体胰岛素与功能化多聚合物结合.
- 修改过的聚合物与酸对葡萄糖的反应.
- 在1型糖尿病小猪中评估配方的生物相容性和体内性能.
主要成果:
- 这种配方显示出异常的生物相容性.
- 在糖尿病小猪中维持正常血糖192小时,仅服用一次剂量.
- 呈现微不足道的低血糖,表明胰岛素的释放受到控制.
结论:
- 功能化聚合物有效增强胰岛素的结合,防止不受控制的释放.
- 这一策略为开发高水平的葡萄糖反应性胰岛素配方提供了一个有前途的方法.
- 开发的配方显示了改善糖尿病治疗的潜力,并减少了治疗负担.
相关概念视频
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
Insulin Formulations: Types and Delivery
648
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
648
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581


